Only LEQVIO® is HCP-administered, with 2 doses a year* for reducing LDL-C1
2 initial doses, then 2 doses a year1
- No dose adjustments
- No refrigeration1
- Single-dose prefilled syringe1
- Shelf life of 3 years2†
- No required post-injection–related safety monitoring
Remember: Do not remove the needle cap until you are ready to inject.
For more information on administration, see the Instructions for Use Flash Card.
*After 2 initial doses and taken with statin therapy.1
†Always check the expiration date on the prefilled syringe before administration.
Once administered, no chance of a missed dose for 6 months1*
HCP-administration gives you confidence your patients received their dose.
Alirocumab is dosed every 2 weeks (75 mg-150 mg), equating to 26 injections/year.4 The monthly dose of PCSK9 mAbs is administered by giving 2 or 3 injections consecutively, which equates to 24 to 36 injections/year.3,4
This is not a complete list of all the available treatments to patients with primary hyperlipidemia.
The comparison pertains only to difference in dosing and administration and should not be considered a comparison of efficacy or safety.
*After 2 initial doses and taken with statin therapy.1
LEQVIO administration and additional dosing information
Not actual size.
27 gauge, 1/2-inch needle.5
- LEQVIO is a subcutaneous injection that can be given by any state-certified HCP1
- LEQVIO is administered into the abdomen, upper arm, or thigh1
- Do not remove the needle cap until you are ready to inject1
For more information on administration, see the Instructions for Use Flash Card.
Missed doses
Missed doses < 3 months | Missed doses > 3 months |
If a planned dose is missed by less than 3 months, administer LEQVIO and maintain dosing according to the patient’s original schedule1 | If a planned dose is missed by more than 3 months, start a new dosing schedule—administer initially, again at 3 months, and then every 6 months1 |
In-office administration of LEQVIO:1
- Adds minimal burden to your patient’s existing medication and care regimen
- Reduces LDL-C without adding another daily treatment
- May integrate seamlessly into your patient’s health care routine
For more information on administration, see the Instructions for Use Flash Card.
What do you need to know about LEQVIO dosing
Learn more about LEQVIO administration including injection instructions and key product information.
LDL-C, low-density lipoprotein cholesterol; mAb, monoclonal antibody; MOA, mechanism of action; PCSK9, proprotein convertase subtilisin/kexin type 9.